

CYTOSKELETON PROTEINS IN CHEDIAK-HIGASHI SYNDROME

L. Berrueta¹, F. Dagger², F. Merino³, A. Hernández², B. Esparza³,
H. Montes¹ and J.C. Pérez Cobo³

¹School of Medicine. Universidad de los Andes, Mérida. Venezuela. ²School of Sciences. Biology. Universidad Central de Venezuela. Caraca., Venezuela. ³School of Medicine and Dentistry. Universidad del País Vasco. Bilbao. Spain.

The Chediak-Higashi syndrome (CHS) is a rare genetic disease characterized by the presence of abnormally large cytoplasmic masses in all body granule producing cells. The precise molecular mechanism for this disease is still unknown. We report studies on cytoskeleton protein components in peripheral blood leukocytes and in relation to capping of concanavalin A receptors. Marked increase in spontaneous concanavalin A (Con A) capping and a lower endocytic rate were observed; however, cytochalasin B did not modify this spontaneous capping. Microfilament or associated proteins in CHS cells did not show differences with those of control subjects. Cytoplasmic distribution of tubulin and microtubule associated proteins were similar to that of controls. However, we noted an atypical cellular distribution to tyrosinolated tubulin and to anti MAP-1 antibodies; and by SDS-gel electrophoresis a diminished intensity of tyrosinolated tubulin was also detected. In CHS leukocytes a decrease reactivity to antibodies to band 3 transmembrane protein was observed.

Key words: Chediak-Higashi syndrome. Cytoskeleton. protein band 3

ESTUDIOS DEL CITOESQUELETO EN EL SÍNDROME DE CHEDIAK-HIGASHI

El Síndrome de Chediak-Higashi (CHS) es una rara enfermedad genética caracterizada por la presencia de grandes masas citoplásmicas en todas las células del cuerpo productoras de gránulos. El mecanismo molecular de esta enfermedad es todavía desconocido. En este artículo

Mailing address:

Fernando Merino
Departamento de Fisiología
Facultad de Medicina y Odontología
Universidad del País Vasco
48940 Leioa. Vizcaya
Tel.: (34) 4 464 88 00, Fax: (34) 4 464 92 66
E-mail: ofpmenif@lg.ehu.es

culo se describen estudios sobre los componentes del citoesqueleto en leucocitos de sangre periférica y en relación con el fenómeno de coronamiento (capping) de receptores para concanavalina A. Se observó un acentuado coronamiento espontáneo de estos receptores y una disminución de la velocidad de endocitosis, pero la citocalasina B no modificó este coronamiento espontáneo. Los microfilamentos o proteínas asociadas, en las células de este síndrome no mostraron diferencias con aquellas de los sujetos controles. La distribución citoplásmica de la tubulina y de proteínas asociadas a microbulos fue similar a aquella de los controles. Sin embargo, se apreció una distribución atípica de la reacción de los anticuerpos contra la tubulina tirosinada y para la proteína MAP-1. Por electroforesis en gel-SDS se apreció una disminución en la intensidad de la tubulina tirosinada. Una reducción de la reactividad de los anticuerpos contra la proteína banda 3 se pudo apreciar en las membranas de eritrocitos de pacientes con este síndrome.

Palabras clave: Citoesqueleto. Proteína banda 3. Síndrome de Chediak-Higashi.

Abbreviations: COMT: Center of microtubule assay. CHS: Chediak-Higashi syndrome. PMN: Polymorphonuclear neutrophils.

INTRODUCTION

The Chediak-Higashi syndrome (CHS)¹ is a rare genetic, autosomal recessive, disease defined by the presence of large cytoplasmic granules in all body granule producing cells, and characterized by increased size of lysosomes, secretory and pigment granules. The main clinical, and features are due to functional alterations of neutrophils, melanocytes and platelets²⁻⁴; also, an altered cytotoxic T lymphocytes (CTL) and NK cell lytic activity has been well documented.

The precise or basic cell and molecular defects caused by the Chediak-Higashi gene are still unknown and several mechanisms have been postulated⁵⁻⁹ being

one of the proposed hypothesis an impaired microtubule function causing a disorder assembly and defective interactions with membranes.

The main reported evidence for a defective microtubule assembly and/or function in these patients has been the spontaneous capping of cell surface concanavalin A receptors by CHS leukocytes and its correction by dibutyryl cGMP and cholinergic agonists⁵⁻¹⁰. However, immunofluorescence and electron microscopy analysis, did not reveal any abnormal qualitative microtubule and microfilament cytoplasmic distribution¹¹⁻¹³. Elevated levels of tyrosine incorporation in CHS neutrophils and higher amounts of tyrosine fixed to tubulin have been described¹⁴. These levels could be increased by the stimulatory effect of the chemoattractant fMet-Leu-Phe. Ascorbate treatment of CHS PMN was able to reduce the rate and extent of post-translational tubuline tyrosine in CHS PMN induced by the fMet-Leu-Phe peptide both *in vivo* and *in vitro*. These results suggested that changes in redox state in stimulated PMN may be linked to the induction of tubulin tyrosination.

Since it has become clear that association between cytoskeleton and membranes plays a significant function in signal transduction pathways¹⁵⁻¹⁷, we have studied membrane components (band 3 protein)^{18,19} and the cytoskeleton, and associated proteins in leukocytes from Chediak-Higashi patients and their relation to membrane receptor mobility.

MATERIALS AND METHODS

Studies were performed in 7 CHS patients, 5 females and 2 males, with ages between 6 months and 19 years. All of them were born in Pregonero or nearby small communities in the State of Táchira, Venezuela, a cluster of "endemic", Chediak-Higashi syndrome⁴. Parents, brothers and sisters of the patients and healthy subjects, as controls, of the same area were also studied. Chediak-Higashi syndrome diagnosis was established by clinical findings and by the presence of large intracytoplasmic azurophilic granules in polymorphonuclear neutrophils in peripheral blood smears.

Isolated peripheral blood lymphocytes and neutrophils were obtained by Ficoll-Hypaque gradient centrifugation. Purified neutrophils were obtained by mild hypotonic shock treatment of isolated cells.

The following specific monoclonal and polyclonal antibodies to cytoskeleton membrane proteins were tested: phalloidin-rhodamine, antibody to actin, anti-polymeric actin, anti-vinculin, anti-actinin, anti α -tubulin, anti-8-globulin (Amershan Lab, USA), and to acetylated and tyrosinated tubulin (SIGMA, USA). Monoclonal JA2, and anti MAP-1 antibody was obtained from Dr. Jan de

Mey (Institute J. Monod, Paris France). The polyclonal antibody directed to the last 15 aminoacids of the transmembrane fragment of the erythrocyte band 3 membrane protein, was a gift from Dra. Ana M. García, (EISA Laboratories, Boston, USA). Rhodamine-labelled monoclonal anti-mouse immunoglobulins were commercially obtained (Coulter, USA). Antibodies to globular actin, actinin, vinculin, MAP-1 and to the band 3 transmembrane fragment were diluted 1:500; tyrosinated tubulin 1:800; phalloidin rhodamine 1:50; and anti-acetylated tubulin 1:10.

Distribution pattern of cytoskeleton membrane proteins in CHS cells was studied by indirect immunofluorescence assay. To such end Ficoll-Hypaque isolated cells were layered on polylysine coated cover slips and fixed with 3% paraformaldehyde (PAF) for 10 min. Cells were then washed with PBS-NH₄Cl 50mM (SIGMA) and permeabilized with 0.1 Triton X-100 (Sigma, USA) for 2 min after which, cells were washed with PBS-gelatin. Cells were then incubated with antibody dilution for 30 min, washed with PBS-gelatin three times and incubated with rhodamine labelled anti mouse monoclonal antibodies for 30 min. After washing with PBS-gelatin and then with PBS three times more, cells were mounted in Moviol (Hoechst, Germany). Large intracytoplasmic granules were visualized by staining them with 0.01 % acridine orange (Merck, Germany). Antibody reactions were visualized in a Leitz epifluorescence microscope.

Concanavalin A receptor mobility was studied at 2, 5, 10, 15 and 30 min. Cells (2×10^6) were incubated with Con A-FITC, 10 mg/ml in PBS at 4°C; the cells were brought and kept for the desired time at 37°C; the reaction was stopped by the addition of 3% PAF, for 10 min and after washing three times mounted in Moviol and examined by fluorescence microscopy. The presence and/or distribution of cytoskeleton membrane proteins in relation to cap formation, were detected after 15 min Con A-FITC incubation at 37°C.

The effect of Colchicine, Cytochalasine B and sodium azide on the membrane receptor mobility in CHS leukocytes, was examined by incubating 2×10^6 cells with 10^{-6} M Colchicine, 10 μ g of Cytochalasine B or 20 mM sodium azide for 30 min at 37°C; after washing with PBS, cells were incubated with Con A-FITC for 2 min at 4°C, washed three times, fixed with 3% PAF, washed with PBS, mounted in glycerol and observed under fluorescence microscope.

The analysis of cytoskeleton cell proteins electrophoretic pattern in CHS neutrophils and controls was determined by SDS polyacrylamide gel electrophoresis. Ficoll-Hypaque isolated neutrophils, 10^7 cells/ml, were incubated at 4°C for 30 min with lysis buffer pH 8.3, composed of 1 % Nonidet P-40, 0,5% sodium deoxycho-

late in Tris-EDTA buffer. After centrifugation at 7000g for 20 min to eliminate the nucleus, the supernatant was treated with 1 mM PMSF, phenylmethyl sulphonyl fluoride, a protease inhibitor, in ethanol. Electrophoresis was performed in 10 % SDS-PAGE in Mercaptoethanol containing Tris Buffer and in a Mini-Protean 11 cell (BioRad, USA) at 100 volt in Tris-base²⁰. Identification of tyrosinated tubulin was performed after protein transfer to nitrocellulose acetate membranes (Bio-Rad, USA), and by their reaction with monoclonal antibody to tyrosinated tubulin. To such end, membranes were first incubated for 24 hrs in a blocking solution composed of 3 % BSA Tris-HCL buffer solution; and after their washing, were incubated with anti tyrosinated tubulin monoclonal antibody at 1:300 dilution in the blocking buffer solution. After washing 3 times, membranes were incubated for 1 hr in a Protein A-peroxidase solution (Sigma, USA) at 1:100 dilution. Reaction was developed with Diaminobencidine (DAB, Sigma) in H₂O₂.

RESULTS

Direct and indirect immunofluorescence studies exhibited differences in the distribution pattern of some cytoskeleton and transmembrane proteins of CHS cells as compared to controls (Table 1).

Cell distribution of the anti alfa-tubulin or anti beta-tubulin antibody reactivity in both, normal and CHS mononuclear cells and neutrophils, was variable with no special association and the center of microtubule organization was observed in some samples.

Tyrosinated tubulin antibody reaction in neutrophils from CHS patients did not show specific cytoplasmic location; visualizing a diffuse pattern of immunofluorescence; this in contrast with that of controls and CHS heterozygous cells where this reaction was found to be associated to cytoplasmic granules (Figure 1). Interestingly enough, the 19 years old CHS patient showed a cell pattern similar to that of controls. Anti acetylated tubulin antibody gaved a diffuse reaction pattern and no differences among the three studied groups were evidenced.

In CHS Con A cap forming lymphocytes and neutrophils, tyrosinated tubulin reaction also differed from that of control cells: CHS leukocytes showed a cytoplasmic diffuse pattern of , but, in controls was observed in the cap region. In cells from the 19 years antibody reactivity old CHS patient, again, a normal cell type pattern was observed. Microtubule associated protein MAP-1 , detected by the monoclonal antibody JA2, was frequently observed to be associated with cac regions in

Table 1. Cell distribution patterns of cytoskeleton and transmembrane proteins in Chediak-Higashi syndrome and control lymphoid cells

Antibodies to Proteins	Controls	Distribution patterns in:	
		CHS Patients	CHS Heterozygous
Tyrosinated tubulin	Associated to granules	Not associated	Associated to granules
Acetylated tubulin	Diffuse	Diffuse	Diffuse
Ttubulin -α	Variable distribution, with no special association COMT was observed in some special samples.		
Tubulin-β	Variable	Variable	Variable
MAP-I	Variable	Cap region	Variable
Globular actin	Membrane associated	Membrane associated	Membrane associated
Phalloidin	Membrane associated	Membrane associated	Membrane associated
Actinin	Membrane associated	Membrane associated	Membrane associated
Vinculin	Membrane associated	Membrane associated	Membrane associated
Band 3	Strong, diffuse fluorescence	Faint fluorescence	Faint fluorescence

CHS cells, whereas, it showed a variable distribution in cells from normal subjects and heterozygous CHS subjects.

Microfilament protein components did not show differences in either, distribution or fluorescence intensity, between CHS patients and control subjects. In both, globular and polymeric (phalloidin) actin, a peripheral distribution closely linked to the cell membrane was observed; and in some CHS leukocytes association with membrane patches and caps was noted. Similarly, actinin and vinculin were found to be membrane associated. Also, no significant differences were detected in the beta-tubulin cell distribution. Anti alpha-tubulin reactivity was also similar in CHS and controls showing no special association; a diffuse distribution was observed in mononuclear cells and neutrophils of both controls and CHS patients; with, in some cells, association to the center of microtubule organization.

Anti Band 3 antibody showed a faint immunofluorescence reaction in CHS cells as compared to that of controls (Figure 2). In the 19 years old CHS patient, the fluorescence intensity was similar to that of controls.

The Con A cell membrane receptor interaction in lymphocytes and neutrophils was markedly different between CHS patients and controls. At 4°C a uniform cell membrane pattern was observed in controls and CHS heterozygous; however, capping was already formed in 90% of the cells, neutrophils and lymphocytes, from CHS patients (Figure 3). At 37°C, fluorescence in normal cells changed from patches to capping and finally to endocytosis; this, endocytosis by CHS cells was delayed, being still observed after 1 hour incubation at 37°C (Table 2). It should be noted that the 19 years old CHS patient behaved




Figure 1. Peripheral blood neutrophils from Chediak-Higashi patient (lower) and control subject (upper) stained with anti-tirosinated tubulin antibodies 1d showing a cytoplasmic granule association in normal cells and a diffuse or non associated pattern in CHS neutrophils.

somewhat intermediate between other patients and controls: a high percent of cells were already spontaneously capped at 4°C, 100% capping at 37°C.

Con A capping in Colchicine treated control cells (at 4°C/2 min) was similar to that seen in untreated CHS cells: 100% spontaneous cap formation. An opposite effect, no cap formation, was seen when normal cells were treated with Cytochalasine B at 37°C for 30 min. However, in CHS cells cytochalasine B did not change the increased Con A membrane receptor mobility (Table 3). When normal cells were treated with sodium azide, a metabolic inhibitor, cap formation at 37°C was inhibited up to 30 min of incubation time; this showing that capping is energy dependent and coupled to cell metabolism. In CHS cells, sodium azide did not have any effect, showing a similar fluorescence pattern to that of untreated cells.

By electrophoretic analysis we tried to determine whether there could be differences in the pattern of CHS

Table 2. Kinetics of cell membrane receptors in CHS patients

Temperature	Time	Distribution patterns in:	
		Controls	CHS Patients
4°C	2 min	Membrane uniform	Cap
37°C	5 min	Membrane aggregates	Cap
37°C	10 min	Membrane aggregates	Cap
37°C	15 min	Cap	Cap
37°C	30 min	Endocytosis	No endocytosis

Table 3. Drug effect on the kinetics of cell membrane receptors mobility in CHS patients

Drug	Time	Temperature	Distribution patterns in :	
			Controls	CHS patients
Colchicine	2 min	4°C	Cap	Cap
Sodium azide	30 min	37°C	Membrane uniform	Cap
Cytochalasine	30 min	37°C	Membrane uniform	Cap

neutrophil cell proteins as compared to that of normal cells; specially those of the membrane cytoskeleton. In SDS-PAGE electrophoresis of protein extracts from normal cells, some protein bands were easily visualized, specially one with a molecular weight of approximately 50-55 kDa. This protein in immunotransference studies was identified as alpha-tubulin and tyrosinated tubulin. The second peptide detected was of low molecular weight, 43

kDa (a molecular weight similar to that of actin monomers). Some high molecular weight proteins were also seen. The electrophoretic pattern was rather similar in all control subjects studied.

Since neutropenia is a common feature in Chediak-Higashi syndrome patients, a rather low amount of proteins is extracted. Therefore, the study of CHS neutrophil proteins presents great technical difficulties. To overcome this problem, we used the silver nitrate staining instead of Coomassie Blue for protein detection in gels. This technique allows detection of quantities in the order of nanograms and enhances visualization of small peptides. Despite these difficulties, it could be recognized that in the gels from CHS neutrophil proteins, the 50-55 kDa protein was very faintly stained as compared to controls (even though similar amounts of proteins were used) (Figure 4). This suggests that tyrosinated tubulin was decreased in CHS cells.




Figure 2. Peripheral blood mononuclear cells from control subject (upper) and Chediak-Higashi patients (lower) stained with anti band 3 antibodies and showing a different degree of fluorescence staining intensity.

DISCUSSION

Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disorder affecting cellular membranes and characterized by the formation of giant organelles in many different cell types. However, only cells such as, neutrophils, melanocytes, CTL populations, NK cells, macrophages and platelets, are both, morphologically affected and functionally defective. Cells such as fibroblasts, mast cells, renal and acinar pancreatic cells are estructurally but not functionally influenced.

The basic cell and molecular defect caused by the CHS gene remains to be fully established. Recent evidence in the literature has indicated that CHS cells affected by the CHS gene show: a) a defective vesicular transport to and from lysosomes and late endosomes²¹; b) aberrant compartmentalization of lysosome and granular enzymes and abnormal trafficking of some cellular proteins²²; and c) an inability to secrete the protein content of their giant granules: defective degradation by neutrophils, NK cells and CTL clones^{7,8,23}.




Figure 3. Peripheral blood mononuclear cells from control subjects (upper) and Chediak-Higashi patients (lower) incubated with concanavalin A-FITC at 4°C for 2 minutes, and showing a diffuse staining membrane immunofluorescence pattern with sparse aggregates in control cells and spontaneous capping formation under similar condition by CHS lymphocytes.

The formation of the typical large organelles by CHS cells has been hypothesized to be produced by an increased or abnormal cytoplasmic granular aggregation and fusion. This, can be the result of changes in membrane fluidity²⁴; to the inability to secrete their giant granules content due to an altered protein involved in membrane fusion²⁵; or to an altered protein involved in vesicle transport and distribution²¹.

The CHS gene was associated²⁵ and has recently been mapped to chromosome 1 (1q42-44)²⁶⁻²⁹, and it has been postulated that this gene may define a novel gene family²⁹. Even though, the gene product still remains elusive, several hypothesis have been advanced: relationship with proteins associated with vesicle transport; homology to stathmin, a phosphoprotein that regulates the polymerization of microtubules; and its role as a component of a membrane-associated signal transduction complex that regulates intracellular protein trafficking.

The results presented in this paper indicated that CHS lymphocytes and neutrophils exhibited differences

in the cellular, cytoplasmic, distribution of some cytoskeleton proteins, and a decrease in the anionic band 3 protein. These results seem to be similar to previously described observations in the literature. Perinuclear accumulations of tyrosinase, TRP-1, and granulophysin, and excessive cellular translocation of tyrosinase-containing vesicles have been described in cultured melanocytes²² and interpreted as been due to an abnormal trafficking of some cellular proteins. Platelet membrane glycoprotein abnormalities³⁰, as well as a decrease of some transmembrane proteins such as the Na⁺/K⁺ ATPase in Chediak-Higashi erythrocyte membranes³¹ and the Ca²⁺ pump in beige mouse lysosomes membranes⁷ have also been reported. The herein described observations can, therefore, be attributed to abnormal protein trafficking since it is well known that the attachment of these integral membrane proteins to the cytoskeleton may also involve protein sorting. These observations are also compatible with the postulated role of the CHS putative gene product in the regulation of intracellular protein trafficking²⁹.

As has been previously described^{5,6}, an increased spontaneous concanavalin A cap formation similar to that of colchicine treated cells was observed. Cytochalasin B, a drug which interferes with actin filament polymerization by specifically interacting with their ends, inhibited cap formation by normal cells, but did not modify the spontaneous capping observed in CHS patients. Interestingly, an "atypical" CHS patient because of her age, 19 years old, (most CHS patients perish at about 6 years of age) showed what could be called an "intermediate type" of receptor membrane mobility, even




Figure 4. Immunotransference reaction with anti-tyroinated tubulin antibody in (b) control subject, (c) CHS heterozygous, (d) 19 years old CHS patient and (e) CHS patient. (a) molecular weight markers.

though spontaneous caps were produced in about 40% of the cells when incubated with Con A-FITC at 4°C, and the remainder cells showed membrane patches similar to control cells, 100% caps were formed upon incubation at 37°C. This observation seems to indicate that some CHS patients may be less severely affected by the anomalous gene, probably due to a less gene penetrance.

ACKNOWLEDGMENTS

Part of this work were supported by grants from the Vicerrectorado de Investigación, Universidad del País Vasco, Spain, and from the Consejo Nacional de Ciencia y Tecnología, Venezuela, to one of us (F.M.).

REFERENCES

1. Béguez César CA. Neutropenia crónica maligna familiar con granulaciones atípicas de los leucocitos. *Bol Soc Cubana Pediat* 1943; 15: 900-922.
2. Blume RS, Wolf SM. The Chediak-Higashi syndrome: studies in four patients and a review of the literature. *Medicine* 1972; 51: 247-280.
3. Merino F. Immunodeficiency to Epstein-Barr virus in Chediak-Higashi syndrome. In: *Immune deficiency and Cancer. Epstein-Barr Virus and Lymphoproliferative Malignancies.* (Purtilo, D.T., Ed.), Plenum Press, New York, 1984. pp. 143-164.
4. Ramírez-Duque P, Arends T, Merino F. Chediak-Higashi syndrome: Description of a cluster in a Venezuelan andean isolated region. *J Medicine* 1982; 13: 431-451.
5. Oliver JM, Zurier B, Berlin RD. Concanavalin A cap formation on polymorphonuclear leukocytes of normal and beige Chediak-Higashi mice. *Nature* 1975; 253: 471-473.
6. Haak RA, Ingraham LM, Baehner RL, Boxer LA. Membrane fluidity in humans and mouse Chediak-Higashi leukocytes. *J Clin Invest* 1979; 64: 138-144.
7. Styrt B, Pollack CR, Klempner MS. An abnormal calcium uptake pump in Chediak-Higashi neutrophil lysosomes. *J Leukoc Biol* 1988; 44: 130-135.
8. Baetz K, Isaaz S, Griffiths GM. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. *J Immunol* 1995; 154: 6122-6131.
9. Merino F, Esparza B, Sabino E. Chediak-Higashi syndrome natural killer cells: a protein kinase C defective activation/regulation defect? *Eur J Pediatrics* 1996; 155: 254-255.
10. Oliver JM. Impaired microtubule function correctable by cyclic GMP and cholinergic agonists in the Chediak-Higashi syndrome. *Am J Pathol* 1976; 85:

- 395-418.
11. Frankel FR, Tucker RW, Bruce J, Stenberg R. Fibroblasts and macrophages of mice with the Chediak-Higashi-like syndrome have microtubules and actin cables. *J Cell Biol* 1978; 79: 401-408.
12. Ostlund RE, Tucker RW, Leung JT, Okun N, Williamson JR. The cytoskeleton in Chediak-Higashi syndrome fibroblasts. *Blood* 1980; 56: 806-811.
13. White JG, Clawson CG. The Chediak-Higashi syndrome: microtubules in monocytes and lymphocytes. *Am J Hematol* 1979; 7: 349-356.
14. Nath J, Flavin M, Gallin JI. Tubulin tyrosylation in human normal polymorphonuclear leukocytes: studies in normal subjects and in patients with the Chediak-Higashi syndrome. *J Cell Biol* 1982; 95: 519-526.
15. Mills JW, Mandel LJ. Cytoskeletal regulation of membrane transport events. *FASEB J* 1994; 8: 1161-1165.
16. Cowin P, Burke B. Cytoskeleton membrane interactions. *Current Opin Cell Biol* 1996; 8: 56-65.
17. Zigmond SH. Signal transduction and actin filament organization. *Current Opin Cell Biol* 1996; 9: 66-73.
18. Stack TL. The band 3 protein of the human red cell membranes: a review. *J Supra Struct* 1978; 8: 311-324.
19. Cabantchik ZI, Knauf PA, Rothstein A. The anion transport system of the blood cell. The role of membrane protein evaluated by the use of probes. *Biochim Biophys Acta* 1978; 515: 239-302.
20. Lemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 1970; 227: 680-685.
21. Burkhardt JK, Wiebel FA, Hester S, Argon V. The giant organelles in beige and Chediak-Higashi fibroblasts are derived from late endosomes and mature lysosomes. *J Exp Med* 1993; 178: 1845-856.
22. Zhao H, Boissy VL, Abdel-Malek Z, Zing RA, Nordlund JJ, Boissy RE. On the analysis of the pathophysiology of Chediak-Higashi syndrome. Defects expressed by cultured melanocytes. *Lab Invest* 1994; 71: 25-34.
23. Baetz K, Isaaz S, Griffiths GM. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. *J Immunol* 1995; 154: 6122-6131.
24. Boxer LA, Smolen JE. Neutrophil granule constituents and their release in health and disease. *Hematol Oncol Clin N Amer* 1988; 2: 101-134.
25. Salamanca-Gomez F, Salazar-Mallen M, Amezcua ME. Chromosome one polymorphism in a girl wit-

- hin the Chediak-Higashi syndrome. *Acta Cytol* 1978; 22: 402-405
26. Barbosa MDFS, Nguyen GA, Tchernev VT, Ashley JA, Detter JC, Blaydes SM, Brandt SJ, Chotai D, Hodgmall C, Solari RCE, Lovett M Kingsmore SF. Identification of the Homologous Beige and Chediak Higashi Syndrome Genes. *Nature* 1996; 382: 262-265.
 27. Barrat FJ, Auloge L, Pastural E, Lagelouse RD, Vilmer E, Cant AJ, Weissenbach I, Lepaslier D, Fischer A, Desaintbasile G. Genetic and Physical Mapping of the Chediak Higashi Syndrome on Chromosome 1q42-43. *Am J Human Genet* 1996; 59: 625-632.
 28. Fukai K, Oh J, Karim MA, Moore KJ, Kandil HH, Ito H, Burger J, Spritz RA. Homozygosity Mapping of the Gene for Chediak Higashi Syndrome to Chromosome 1q42-44 in a Segment of Conserved Synteny That Includes the Mouse Beige Locus (Bg). *Am J Human Genet* 1996; 59: 620-624.
 29. Nagle DL, Karim MA, Wmlf EA, Holmgren L, Bork P, Misumi DJ, Mcgrail SH, Dussault BJ, Perou CM, Boissy RE, Duyk GM, Spritz RA, Moore KJ. Identification and Mutation Analysis of the Complete Gene for Chediak Higashi Syndrome. *Nature Genetics* 1996; 14: 307-311.
 30. Ledezma E, Apitz Castro R. Protein and glycoprotein abnormalities in platelets from human Chediak-Higashi syndrome: polyacrylamide gel electrophoretic study of platelets from five patients. *Thromb Res* 1985; 40: 19-28.
 31. Proverbio T, Proverbio F, Marin R, Merino F. Na⁺,K⁺-ATPase activity in red blood cells from patients with Chediak-Higashi syndrome. *Exp Mol Pathol* 1995; 62: 173-179.